Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fractyl Health, Inc. ( (GUTS) ) has issued an announcement.
On January 29, 2026, Fractyl Health reported six-month randomized interim data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita for maintaining weight loss after GLP-1 drug discontinuation. Revita-treated patients showed lower weight regain than the sham group at six months, with an especially pronounced effect in those who had above-median GLP-1-induced weight loss, alongside improvements in lipid parameters, reduced sweet-food cravings and a clean safety profile with no device- or procedure-related serious adverse events and no discontinuations due to adverse events. The company has asked the U.S. Food and Drug Administration to consider reviewing Revita under the De Novo pathway, reflecting its low-to-moderate risk profile, and outlined a series of 2026 clinical and regulatory milestones that could culminate in a pivotal data readout and a potential U.S. marketing application, underscoring Revita’s bid to become a first-in-class procedural therapy for post-GLP-1 weight maintenance and potentially shifting the competitive landscape in obesity care.
The most recent analyst rating on (GUTS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
The score is held back primarily by very weak financial performance (large losses, heavy cash burn, and slightly negative equity). Offsetting this, earnings-call updates point to meaningful clinical progress and funded near-term runway with multiple catalysts, while technicals are neutral-to-modestly supportive and valuation remains pressured due to ongoing losses and no dividend.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc., based in Burlington, Massachusetts, is a metabolic therapeutics company developing disease-modifying treatments targeting the root causes of obesity and type 2 diabetes. Its lead product candidate, Revita, is a minimally invasive endoscopic procedure designed to remodel the duodenal lining to restore metabolic signaling, and it holds FDA Breakthrough Device designation for weight maintenance in people with obesity who discontinue GLP-1 therapies.
Average Trading Volume: 3,378,745
Technical Sentiment Signal: Hold
Current Market Cap: $290.5M
Learn more about GUTS stock on TipRanks’ Stock Analysis page.